Use of prescription stimulants doubled from 2006 to 2016 in the United States1 and, as of 2013, it resulted in more pharmaceutical expenditures for children than any other medication class.2 Although the rise in stimulant use parallels increasing attention-deficit/hyperactivity disorder diagnosis rates, stimulants, even when appropriately prescribed, are commonly diverted and used nonmedically.3 It is important to consider factors that may contribute to a potential oversupply of stimulants. Pharmaceutical company marketing is associated with increased prescribing.4 The extent to which physicians receive marketing for stimulants is not well described.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hadland SE, Cerdá M, Earlywine JJ, Krieger MS, Anderson TS, Marshall BDL. Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018. JAMA Pediatr. 2020;174(4):385–387. doi:10.1001/jamapediatrics.2019.5526
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: